Physician-reviewed · DPIIT-recognized

Pharmacally

Menarini

Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.

Latest in Menarini

1 stories · every one Fact-Checked

Sort

Menarini and Georgiamune GIM-621 preclinical oral immunotherapy licensing deal for solid tumors

Mergers & AcquisitionsMenarini Bets on Georgiamune’s GIM-621 With $1.1B DealMenarini Group and Stemline Therapeutics have secured exclusive worldwide rights to Georgiamune’s preclinical oral immunotherapy GIM-621 in a deal worth up to $1.1 billion, plus royalties.22 Oct 2026 · 3 min read

Page 1 of 1

Explore more

Health TidingsIndustry, pipeline and company news.

RegulatoryApprovals, policy and agency decisions.

ResearchPeer-reviewed studies and scientific breakthroughs.

Drug FinderLook up any drug: uses, dosing and safety.

From the HistoryLandmark moments in pharmaceutical history.

LatestEvery new story, as soon as it is published.